The Effects of Ninjinyoeito on Impaired Spatial Memory and Prefrontal Cortical Synaptic Plasticity through α-Amino-3-hydroxy-5-4-isoxazole Propionic Acid Receptor Subunit in a Rat Model with Cerebral Ischemia and β-Amyloid Injection

• Published in: Evidence-based complementary and alternative medicine 2023-01, Vol.2023 (1), p.6035589-6035589
• Main Authors: Nagao, Masaki, Hatae, Akinobu, Mine, Kazuma, Tsutsumi, Soichiro, Omori, Hiroya, Hirata, Marika, Arimatsu, Maaya, Taniguchi, Chise, Watanabe, Takuya, Kubota, Kaori, Katsurabayashi, Shutaro, Iwasaki, Katsunori
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Anorexia; Antibodies; Ca2+/calmodulin-dependent protein kinase II; Calmodulin; Carotid arteries; Cerebral blood flow; Cognitive ability; Dementia; Dementia disorders; Drug dosages; Glutamate receptors; Glutamatergic transmission; Hippocampus; Ischemia; Kinases; Memory; Neurodegenerative diseases; Neuroplasticity; Neurosciences; Older people; Oral administration; Patients; Phosphorylation; Prefrontal cortex; Propionic acid; Proteins; Spatial memory; Synaptic plasticity; Veins & arteries; β-Amyloid
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2023/6035589

Ninjinyoeito (NYT), a traditional Japanese medicine, is effective for improving physical strength and treating fatigue and anorexia. Recently, a clinical report revealed that NYT ameliorates cognitive dysfunction in Alzheimer’s disease (AD) patients, although the mechanisms remain unclear. AD is a neurodegenerative disorder accompanied by a progressive deficit in memory. Current therapeutic agents are largely ineffective in treating cognitive dysfunction in AD patients. In this study, we investigated the effects of NYT on spatial memory impairment in a rat model of dementia. Rats were prepared with transient cerebral ischemia and intraventricular injection of β-amyloid1-42 for 7 days (CI + Aβ). NYT was orally administered for 7 days after cerebral ischemia. We evaluated spatial memory using the Morris water maze and investigated the expression of α-amino-3-hydroxy-5-4-isoxazole propionic acid receptor subunits, the phosphorylation level of glutamate receptor A (GluA)1 at serine sites S831 and S845, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the hippocampus and prefrontal cortex of CI + Aβ rats. In the CI + Aβ rats, NYT treatment shortened the extended time to reach the platform. However, NYT did not restore the decrease in the hippocampal GluA1, GluA2, or CaMKII expression but increased prefrontal cortical phosphorylation levels of S845-GluA1 and CaMKII. Therefore, NYT may alleviate spatial memory impairment by promoting glutamatergic transmission involved in the phosphorylation of S845-GluA1 and CaMKII in the prefrontal cortex of CI + Aβ rats. Our results suggest that NYT is a valuable treatment for AD patients.